<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(6)</volume><submitter>Lamirault G</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Although autologous bone marrow cell (BMC) therapy has emerged as a promising treatment for acute myocardial infarction (AMI), trials reported mixed results. In the BONAMI trial, active smoking reduced cardiac function recovery after reperfused AMI. Therefore, we hypothesized that variability in the functionality of BMCs retrieved from patients with cardiovascular risk factors may partly explain these mixed results. We investigated the characteristics of progenitor cells in active smokers and non-smokers with AMI and their potential impact on BMC therapy efficacy.&lt;h4>Methods&lt;/h4>Bone marrow and blood samples from 54 smoking and 47 non-smoking patients enrolled in the BONAMI cell therapy trial were analyzed.&lt;h4>Results&lt;/h4>The white BMC and CD45dimCD34+ cell numbers wer</pubmed_abstract><journal>Stem cell research &amp; therapy</journal><pagination>152</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4054959</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.</pubmed_title><pmcid>PMC4054959</pmcid><pubmed_authors>Forest V</pubmed_authors><pubmed_authors>Lemarchand P</pubmed_authors><pubmed_authors>Delasalle B</pubmed_authors><pubmed_authors>Lamirault G</pubmed_authors><pubmed_authors>Roncalli J</pubmed_authors><pubmed_authors>Rouard H</pubmed_authors><pubmed_authors>Van Belle E</pubmed_authors><pubmed_authors>Richard MJ</pubmed_authors><pubmed_authors>Persoons V</pubmed_authors><pubmed_authors>Hemont C</pubmed_authors><pubmed_authors>Le Corvoisier P</pubmed_authors><pubmed_authors>Sportouch C</pubmed_authors><pubmed_authors>Parini A</pubmed_authors><pubmed_authors>Susen S</pubmed_authors><pubmed_authors>Piot C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Difference in mobilization of progenitor cells after myocardial infarction in smoking versus non-smoking patients: insights from the BONAMI trial.</name><description>&lt;h4>Introduction&lt;/h4>Although autologous bone marrow cell (BMC) therapy has emerged as a promising treatment for acute myocardial infarction (AMI), trials reported mixed results. In the BONAMI trial, active smoking reduced cardiac function recovery after reperfused AMI. Therefore, we hypothesized that variability in the functionality of BMCs retrieved from patients with cardiovascular risk factors may partly explain these mixed results. We investigated the characteristics of progenitor cells in active smokers and non-smokers with AMI and their potential impact on BMC therapy efficacy.&lt;h4>Methods&lt;/h4>Bone marrow and blood samples from 54 smoking and 47 non-smoking patients enrolled in the BONAMI cell therapy trial were analyzed.&lt;h4>Results&lt;/h4>The white BMC and CD45dimCD34+ cell numbers wer</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013</publication><modification>2026-04-30T21:34:50.969Z</modification><creation>2026-04-15T03:09:21.187Z</creation></dates><accession>S-EPMC4054959</accession><cross_references><pubmed>24423369</pubmed><doi>10.1186/scrt382</doi></cross_references></HashMap>